Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...
Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.
As an investor in Eli Lilly stock, I'm encouraged by the company's forward thinking. Not only is management making moves to ...
Eli Lilly (LLY) partners with British government for a first-of-its-kind real-world study on economic effects of its weight ...
The justices are considering an effort challenging longstanding case law blocking the state’s ability to probe inflated drug ...
Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...
MangoRx remains committed to its mission and plans to continue to enhance patient care by offering new and innovative solutions while striving to comply with federal, state and local regulatory ...
Eli Lilly has thrown its weight behind a cause beyond the traditional remit of pharma companies. | Eli Lilly has thrown its ...